Elizabeth A. Brem, MD, discusses the shift she has seen in the community setting when it comes to using bispecific antibody ...

The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...

Antonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing ...

Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute myeloid leukemia.